Researchers continue to screen blood for factors that signal neurodegenerative disease.
G8 leaders set 2025 as their goal to find better treatment for Alzheimer's and vowed to coordinate research and care strategies.
The April issue of Health Affairs is dedicated to Alzheimer’s. Authors gathered in Washington, D.C., to articulate how world policy could take shape.
Exome sequencing identifies a new Alzheimer’s risk gene—phospholipase D3.
Novartis to Partner with Banner Health on ApoE4 Prevention Trial Crenezumab Disappoints in Phase 2, Researchers Remain Hopeful Alzheimer’s Disease: In the Eye of the Patient? References and Thresholds—Amyloid Imaging Protocols Debated at AAIC Anti-Amyloid ...
Researchers at BACE meeting explore how trafficking and degradation of the protease relate to amyloid pathology in AD.
Are New Cognitive Tests Ready For Preclinical Trials? Do Tau Tracers Track Cognitive Decline in Disease? Growth Factor Therapy: Safe in Phase 1, Awaiting Efficacy Data Clinical Trials on Alzheimer’s Disease 2013 ...
Older people improved memory and attention after playing a challenging video game, supporting the idea that multitasking could have benefits for cognition.
Studies reported at AAIC demonstrate that biomarkers help predict who will develop cognitive impairment and dementia.
In a large retrospective study, people with the highest plasma levels of an inflammatory protein experienced the greatest decline in reasoning abilities over the next 10 years.
A close-up of the protein mayhem within the synaptic bouton offers scientists an unprecedented glimpse of the activity inside.
Researchers are increasingly branching out from their old focus on Aβ and tau to understand how these proteins intersect with physiological processes and new genetic regulatory mechanisms in the aging brain.
Do blood components really leak across an inflamed blood-brain barrier early on in the development of Alzheimer’s disease? Some GWAS hits and budding neuro-imaging and fluid markers are helping researchers find out.
At AAIC 2014, crenezumab Phase 2 trial results stirred debate.
A mouse study testing the combined effects of a BACE inhibitor and plaque-clearing antibody builds new support for a combination strategy aimed at reducing Aβ buildup in people.